Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald Sells 1,652 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 1,652 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total transaction of $528,193.96. Following the transaction, the executive vice president owned 21,860 shares in the company, valued at approximately $6,989,297.80. The trade was a 7.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Monday, March 2nd, Kevin Joseph Fitzgerald sold 1,598 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $327.65, for a total value of $523,584.70.
• On Tuesday, February 17th, Kevin Joseph Fitzgerald sold 2,041 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $331.96, for a total value of $677,530.36.
• On Friday, February 13th, Kevin Joseph Fitzgerald sold 1,959 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $310.08, for a total transaction of $607,446.72.
• On Tuesday, January 13th, Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $370.33, for a total value of $848,055.70.
• On Monday, January 12th, Kevin Joseph Fitzgerald sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total value of $547,933.70.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock traded up $8.65 during midday trading on Wednesday, hitting $327.30. The company had a trading volume of 931,139 shares, compared to its average volume of 1,481,848. The company has a fifty day simple moving average of $357.29 and a 200 day simple moving average of $417.03. The stock has a market cap of $43.41 billion, a price-to-earnings ratio of 191.40 and a beta of 0.36. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same period last year, the firm earned ($0.65) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 84.9% compared to the same quarter last year. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently modified their holdings of ALNY. Groupama Asset Managment boosted its position in Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares during the last quarter. Norges Bank purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $895,816,000. Arrowstreet Capital Limited Partnership lifted its stake in Alnylam Pharmaceuticals by 698.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after purchasing an additional 1,185,909 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $369,943,000. Finally, Holocene Advisors LP purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $194,616,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the subject of several analyst reports. Oppenheimer started coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective for the company. Royal Bank Of Canada lowered their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 20th. Wells Fargo & Company dropped their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 20th. Leerink Partners decreased their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research note on Monday, December 15th. Finally, Needham & Company LLC lowered their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.